Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count

Emanuel Burri, Felix Schulte, Jürgen Muser, Rémy Meier, Christoph Beglinger

Emanuel Burri, Felix Schulte, Christoph Beglinger, Gastroenterology and Hepatology, University Hospital Basel, 4031 Basel, Switzerland
Emanuel Burri, Rémy Meier, Gastroenterology, Hepatology and Clinical Nutrition, Cantonal Hospital, 4410 Liestal, Switzerland
Jürgen Muser, Central Laboratories, Cantonal Hospital, 4410 Liestal, Switzerland

Author contributions: Burri E and Beglinger C participated in study concept and design; all authors participated in data acquisition, analysis, interpretation, drafting and critical revision of the manuscript, all of them read and approved the final manuscript.

Supported by: Unrestricted Research Grants (to Burri E) by the Freiwillige Akademische Gesellschaft (Basel, Switzerland) and the Gottfried und Julia Bangert-Rhyner-Stiftung (Bern, Switzerland); Bühlmann Laboratories AG (Schönenbuch, Switzerland) provided the assays to measure ascitic calprotectin. Researchers were independent of funding.

Correspondence to: Dr. Emanuel Burri, MD, Gastroenterology and Hepatology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland; burrie@uhbs.ch
Telephone: +41-61-2652525 Fax: +41-61-2655352
Received: August 14, 2012  Revised: November 1, 2012
Accepted: November 11, 2012
Published online: April 7, 2013

Abstract

AIM: To evaluate the diagnostic capability of calprotectin in ascitic fluid for detecting a polymorphonuclear (PMN) cell count > 250/μL ascites.

METHODS: In this prospective observational study, a total of 130 ascites samples were analysed from 71 consecutive patients referred for paracentesis. Total and differential leucocyte cell counts were determined manually with a Neubauer chamber and gentian-violet stain. Calprotectin was measured in 1 mL ascetic fluid by enzyme-linked immunosorbent assay (ELISA) and a point-of-care (POC) lateral flow assay with the Quantum Blue® Reader (Bühlmann Laboratories). All measurements were carried out in a central laboratory by senior personnel blinded to patient history. A PMN count > 250/μL was the primary endpoint of the study. The diagnostic value of ascitic calprotectin measurement was assessed by comparing to the final diagnosis of each patient that had been adjudicated by investigators blinded to calprotectin values.

RESULTS: The PMN count was > 250/μL in 19 samples (14.6%) from 15 patients (21.1%) and varied widely among the study population (range 10-19 800/μL and 1-17 820/μL, respectively). Spontaneous bacterial peritonitis (SBP) was the final diagnosis in four patients (5.6%). All patients with PMN ≤ 250/μL had negative bacterial culture. PMN count was elevated in five patients with peritoneal carcinomatosis, three with lymphoma, one with neuroendocrine carcinoma, and two with secondary peritonitis due to abdominal perforation. PMN cell counts correlated with ascitic calprotectin. Researchers were independent of funding.

The diagnostic value of ascitic calprotectin measurement was assessed by comparing to the final diagnosis of each patient that had been adjudicated by investigators blinded to calprotectin values.

RESULTS: The PMN count was > 250/μL in 19 samples (14.6%) from 15 patients (21.1%) and varied widely among the study population (range 10-19 800/μL and 1-17 820/μL, respectively). Spontaneous bacterial peritonitis (SBP) was the final diagnosis in four patients (5.6%). All patients with PMN ≤ 250/μL had negative bacterial culture. PMN count was elevated in five patients with peritoneal carcinomatosis, three with lymphoma, one with neuroendocrine carcinoma, and two with secondary peritonitis due to abdominal perforation. PMN cell counts correlated with ascitic calprotectin values (Spearman’s rho; r = 0.457 for ELISA, r = 0.473 for POC). A considerable range of ascitic calprotectin concentrations was detected by ELISA [median 0.43 μg/mL, interquartile range (IQR) 0.23-1.23 (range 0.10-14.93)] and POC [median 0.38 μg/mL, IQR 0.38-0.56 (range 0.38-13.31)]. Ascitic calprotectin levels were higher in samples with PMN > 250/μL, by both ELISA [median (IQR) 2.48 μg/mL (1.61-3.65) vs 0.10 μg/mL (0.10-0.36), P < 0.001] and POC [2.78 μg/mL (2.05-5.37) vs 0.38 μg/mL (0.38-0.41), P < 0.001]. The area under the receiver operating characteristics curve for identifying an elevated PMN count was 0.977 (95%CI: 0.933 to 0.995) for ELISA and 0.982 (95%CI: 0.942 to 0.997) for POC (P = 0.246 vs ELISA). Using the optimal cut-off value for ELISA (0.63 μg/mL), ascitic calprotectin had 94.8% sensitivity, 89.2% specificity, positive and negative likelihood ratios of 8.76 and 0.06 respectively, positive and negative predictive values of 60.0% and 99.0% respectively, and 90.0% overall accuracy. Using the optimal cut-off value for POC (0.51 μg/mL), the respective values were 100.0%, 84.7%, 6.53, 0.00, 52.8%, 100% and 87.7%. Correlation be-
tween ELISA and POC was excellent (r = 0.873, P < 0.001). The mean ± SD of the difference was -0.11 ± 0.48 μg/mL with limits of agreement of + 0.8 μg/mL (95%CI: 0.69 to 0.98) and -1.1 μg/mL (95%CI: -1.19 to -0.91).

CONCLUSION: Ascitic calprotectin reliably predicts PMN count > 250/μL, which may prove useful in the diagnosis of SBP, especially with a readily available bedside testing device.

© 2013 Baishideng. All rights reserved.

Key words: Calprotectin; Ascites; Liver cirrhosis; Spontaneous bacterial peritonitis; Polymorphonuclear cells

Burri E, Schulte F, Muser J, Meier R, Beglinger C. Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count. World J Gastroenterol 2013; 19(13): 2028-2036 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i13/2028.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i13.2028

INTRODUCTION

Liver cirrhosis is the clinical end-stage of different entities of chronic liver disease when patients suffer from substantial mortality and morbidity, both of which are positively correlated with disease severity[1,2]. Ascites is the most common complication, and around 60% of patients with compensated cirrhosis develop ascites within 10 years of disease onset[3]. Spontaneous bacterial peritonitis (SBP) is an important cause of morbidity and mortality in cirrhotic patients with ascites. SBP is estimated to affect 10%-30% of cirrhotic patients hospitalised with ascites, and mortality in this group approaches 30%-50%. Many of these patients are asymptomatic, and it is therefore recommended that all patients with ascites undergo paracentesis at the time of admission to confirm the SBP status[5]. Although SBP is less prevalent in an outpatient setting, it is reasonable to also evaluate the ascitic fluid of outpatients because of the high mortality associated with SBP.

The diagnosis of SBP is based upon the polymorphonuclear (PMN) leukocyte cell count exceeding 250/μL in ascitic fluid[6-7]. Currently, differential cell count is usually performed by a manual method using light microscopy and counting chambers. However, the diagnosis is often delayed when laboratory personnel are not readily available or in the private practice setting where specimens are sent to an offsite laboratory. This is a major drawback, as rapid diagnosis of SBP and immediate initiation of antibiotic treatment is of paramount importance. Alternative methods using automated PMN counting[8,9], reagent strips (urine dipsticks)[10,11], or ascitic lactoferrin[12] have been developed; unfortunately, their diagnostic accuracies are limited and their use is dependent upon availability of laboratory personnel and reagents/components from the commercial source. Therefore, an accurate and convenient method of rapid diagnosis of SBP remains an unmet clinical need.

Calprotectin, a calcium and zinc-binding protein, is detected almost exclusively in neutrophils[20,21], and its presence in body fluids is proportional to the influx of neutrophils[22-23]. However, only one study to date has investigated calprotectin levels in ascites and found higher concentrations in patients with malignant disease than in those with non-malignant disease[14]. In contrast, faecal calprotectin is a well-established marker of inflammation and is used to monitor inflammatory bowel disease[24]. A rapid bedside test has been developed to measure calprotectin in faeces; systematic comparison with the established enzyme-linked immunosorbent assay (ELISA) technique showed good correlation between the two tests’ results[25] and the rapid bedside test has been suggested as an equally valuable tool for diagnosing inflammatory bowel disease[26]. It is possible that such a rapid bedside test may be useful for measuring calprotectin in ascitic fluid to indicate PMN levels and SBP status, however the diagnostic accuracy of such a measurement in ascitic fluid is unknown.

This study was designed to test our hypothesis that calprotectin in ascitic fluid could be useful as a surrogate PMN marker for identifying SBP patients (> 250/μL PMN). To this end, we measured calprotectin in ascites of consecutive patients referred for paracentesis using a rapid bedside test and compared the results to those from the traditional ELISA.

MATERIALS AND METHODS

Setting and participants

In this prospective observational study, we recruited patients with ascites referred for paracentesis to the Department of Gastroenterology and Hepatology at the University Hospital Basel, and to the Department of Gastroenterology, Hepatology and Clinical Nutrition at the Cantonal Hospital Liestal in Switzerland. All patients with ascites were eligible for study enrolment, irrespective of the aetiology of ascites. The decision to perform paracentesis was based on clinical findings evaluated by the referring physician who was otherwise not involved in the study. Exclusion criteria were age < 18 years and recent abdominal surgery (< 3 mo). Standardised patient history, clinical symptoms, and demographic data were obtained from all participants. The study was carried out in accordance with the principles of the Declaration of Helsinki and with pre-approval from the local Ethic Committees of both study sites. All patients provided written informed consent prior to participation in any protocol-specific procedures.

Endpoint

The diagnostic value of ascitic calprotectin measurement was assessed in comparison to the adjudicated final diagnosis. A PMN count > 250/μL was the primary endpoint of the study.
Adjudication of the final diagnosis

One month after study participation, the final diagnosis (SBP) and the aetiology of ascites were independently adjudicated in a blinded fashion by two board-certified gastroenterologists not involved in the patients’ care. Their final assessment was based upon available medical records, including PMN count and the results of all diagnostic investigations, as well as the patient’s response to treatment. Current recommendations were followed[6,7]. The two physicians designated the aetiology of ascites by choosing one or more of the following diagnoses from a standardized list: liver cirrhosis (alcoholic, chronic hepatitis, non-alcoholic steatohepatitis, hemochromatosis, primary biliary cirrhosis, others to be specified), hepatocellular carcinoma, cholangiocellular carcinoma, liver metastasis, peritoneal carcinomatosis, right heart failure, nephrotic syndrome, and others to be specified. If more than one cause of ascites was identified, the leading disorder responsible for the current episode was established and recorded. Any disagreements in the final diagnosis of a given study participant were resolved by consensus with a third clinician who was considered an expert in the field and recruited to independently review and adjudicate the cases.

Paracentesis

Paracentesis was performed under aseptic conditions with the patient in the supine position and the puncture site in the left or right lower quadrant. Prior to needle insertion, ultrasound was performed to visualise the intraabdominal structures. No study participant suffered complications related to the abdominal puncture procedure. All samples for diagnostic testing were immediately collected at the bedside and processed by laboratory personnel without further delay. Specifically, aliquots of approximately 1mL ascites were centrifuged for 15 min at 500 × g. The supernatant phase was transferred to a fresh tube and stored at -20 °C until analysis by ELISA or POC, which occurred within 72 h.

Blood samples were also obtained at this time. The ascites samples were used to measure total cell count, PMN count, calprotectin, albumin, total protein, glucose, and lactate dehydrogenase. In addition, two 10 mL aliquots of ascites were subjected to bacterial culture (bottle method) respectively. The serum-ascites albumin gradient (SAAG) was calculated as the difference of albumin in serum and albumin in ascites.

Differential cell count and cytopathology

All laboratory analyses were performed in the Central Laboratories BL (Schönenbuch, Switzerland) by senior laboratory personnel blinded to patient history and calprotectin levels. Total and differential leukocyte cell counts were determined by the manual method using a Neubauer chamber and gentian-violet staining (Leukotic®; bioanalytic GmbH, Freiburg, Germany). The Central Laboratories BL is accredited according to ISO/IEC 17 025 and ISO 15 189 standards. For all study participants who underwent repeated paracentesis, the cytopathological analysis was performed at least once.

Laboratory-based quantitative calprotectin measurement

Ascitic calprotectin in ascites was assayed using a commercially-available ELISA (Bühlmann Laboratories AG, Schönenbuch, Switzerland) and following the manufacturer’s instructions. Briefly, 10 μL aliquots of the supernatant samples were diluted 1:50 in incubation buffer and 100 μL was applied to a microtiter plate coated with a monoclonal capture antibody highly specific for the calprotectin heterodimeric and polymeric complexes. After incubation, washing and further incubation with a detection antibody conjugated to horseradish peroxidase, the tetramethylbenzidine chromogenic substrate was added. The reaction was terminated by a stop solution and the absorbance (optical density at 450 nm) was measured by spectrophotometry. The measuring range of the test was 0.2-12 μg calprotectin/mL ascites with an intra- and interassay coefficient of 4.7% and 11.3%, respectively.

Point-of-care quantitative calprotectin measurement

The Quantum Blue® quantitative calprotectin lateral flow assay (Bühlmann Laboratories AG) was used for the point-of-care (POC) measurement of ascitic calprotectin. The Quantum Blue® reader is currently marketed for 2500 USD ($), and the test cartridges cost 20 USD per sample and analysis. Aliquots of 60 μL 1:10 diluted ascites samples (20 μL ascites in 180 μL extraction buffer) were pipetted respectively onto the sample loading port of the test cartridge. After a 12 min incubation, the test cartridge was quantitatively read by the Quantum Blue® Reader. The measurement range of the lateral flow test was 0.38-3.8 μg calprotectin/mL ascites, with an interassay coefficient of 15.6%. Specimens with concentrations above this measurement range were further diluted with extraction buffer.

In addition, a random subgroup of samples (n = 17) was immediately measured by POC, without first performing the centrifugation step of processing. These results were compared to the results from the POC measurements obtained in the laboratory setting after processing and storage.

Statistical analysis

All statistical analyses were performed using the SPSS software package, version 19.0 (SPSS Inc., Chicago, IL, United States). A P-value of less than 0.05 indicated statistical significance. Intergroup comparisons were made using the Mann-Whitney U test and the χ² test where appropriate. Correlations between numerical data were determined with the Spearman’s rank correlation coefficient. All hypothesis testing was two-tailed. The Bland-Altman plot was used to assess agreement between ELISA test results and POC test results, in which the differences between the results of the two tests for each individual patient were plotted against the corresponding mean of the two readings. The mean and SD of the differences and the limits of agreement, defined as the mean ± 2 SD of the difference (95%CI), were calculated. Analysis of the receiver operator characteristics (ROC) and calculation of the area under the curve (AUC) were used to evaluate the capability of calprotectin to identify a PMN count >
Results

Patient characteristics

A total of 136 samples from 75 patients were prospectively collected from October 2010 to January 2012. Among these, 130 samples were included in the final analysis, representing 71 patients (94.7% of the total; 40 males and 31 females) with a median age of 64 years (IQR 55-71 years). Sixty-three of the patients (88.7%) had been referred to the lab (after centrifugation) showed that the calprotectin concentrations ranged considerably from the measurements of ascitic calprotectin from the ELISA and the POC test correlated well with the PMN count (r = 0.873, P < 0.001). The degree of agreement between the measurements of ascitic calprotectin from the ELISA and the POC test was calculated according to the following formula: [(true positive test results + true negative test results) / total population]. As this study was exploratory in design, no formal power calculations were carried out.

Table 2 Ascitic fluid analysis

| Variable | PMN count > 250/μL (n = 19) | PMN count ≤ 250/μL (n = 111) |
|----------|-----------------------------|-------------------------------|
| Total cell count | 1300.0 (350.0-19800.0) | 250.0 (10.0-1970.0) |
| PMN count | 553.0 (277.0-1780.0) | 21.0 (1.0-212.0) |
| Albumin, g/L | 13.0 (4.8-16.8) | 7.0 (3.0-10.0) |
| Protein, g/L | 22.0 (9.3-37.5) | 12.0 (8.0-20.0) |
| LDH, U/L | 117.0 (100.8-138.5) | 55.0 (42.0-81.0) |
| Glucose, mmol/L | 7.6 (6.2-9.7) | 7.0 (6.2-8.2) |

Values are given as medians (range) for total cell count and polymorphonuclear cell count (PMN) count and median (25th to 75th percentiles) for all other values. LDH: Lactate dehydrogenase.

Calprotectin measurement in ascitic fluid

The ascitic calprotectin concentrations ranged considerably in the ELISA [median 0.43 μg/mL, IQR 0.23-1.23 (range 0.10-14.93)] and POC test [median 0.38 μg/mL, IQR 0.38-0.562 (range 0.38-13.31)]. However, the calprotectin values measured by the laboratory-based ELISA and the POC test correlated well with the PMN count (r = 0.476, P < 0.001 and r = 0.473, P < 0.001, respectively), and the correlation between the two tests was excellent (r = 0.873, P < 0.001). The degree of agreement between the measurements of ascitic calprotectin from the ELISA and the POC test is illustrated in Figure 1. The mean ± SD of the difference was -0.11 ± 0.48 μg/mL, with limits of agreement of +0.8 μg/mL (95% CI: 0.69 to 0.98) and -1.1 μg/mL (95% CI: -1.19 to -0.91).

Comparative analysis of the POC detection of ascitic calprotectin levels in samples measured at the bedside (unprocessed and processed after centrifugation) and in the lab (after centrifugation) showed that the calprotectin measurements correlated well. For unprocessed samples, r = 0.831 (P < 0.001), and for processed samples, r = 0.656 (P = 0.004).

Diagnostic value of ascitic calprotectin

Ascitic calprotectin levels were higher in samples (n = 19) with PMN > 250/μL, both when measured by ELISA [median (IQR) 2.48 μg/mL (1.61-3.65) vs 0.10 μg/mL (0.10-0.36), P < 0.001] and the POC test [median 2.78 μg/mL and 1.17 820/μL, respectively). PMN count > 250/μL was detected in 19 samples (14.6%) from 15 patients (21.1%). Among the study population, SBP was the final diagnosis for four patients (5.6%) and only one of these four had positive ascitic bacterial cultures (Streptococcus pneumoniae). All bacterial cultures from patients with PMN ≤ 250/μL were negative. Additionally, PMN count was elevated in five patients with peritoneal carcinomatosis (two with ovarian cancer, and one each with gastric, colorectal and pancreatic cancer), in three patients with lymphoma, in one patient with neuroendocrine carcinoma, and in two patients with secondary peritonitis due to an abdominal perforation. All patients with SBP received antibiotic treatment and recovered well. None of the patients died. Table 2 details the findings from ascitic fluid analysis.
patients with liver cirrhosis (95 samples from 54 patients; ELISA AUC 0.987, and POC test AUC 0.982). In addition, when the ascites samples were analysed according to the SAAG > 11g/L (115 samples from 62 patients), the AUCs of ascitic calprotectin were 0.983 for the ELISA and 0.988 for the POC test (data not shown).

**DISCUSSION**

This prospective study evaluated the diagnostic utility of measuring calprotectin in ascites to identify ascitic PMN counts > 250/μL in patients referred for paracentesis, and provides the following new information: Patients with an elevated PMN count (> 250/μL) had higher ascitic calprotectin levels than those with normal cell counts; this finding indicates that calprotectin levels correlate well and reliably with PMN count. It is clinically significant that calprotectin levels in ascitic patients can identify elevated PMN counts using both laboratory-based ELISA and bedside POC testing. Indeed, ascitic calprotectin may serve as a surrogate marker for PMN count and would be amenable to routine SBP screening, especially when measured by a bedside test.

Ascites is commonly found in patients with liver cirrhosis and may promote bacterial translocation, enhancing the risk of SBP 

[38,39]. In our study, four of 71 patients were diagnosed with SBP (5.6%). In general, SBP symptoms are nonspecific and current guidelines recommend paracentesis be performed in all patients with ascites to rule out abdominal infection. The diagnosis of SBP in patients with liver cirrhosis is based on a PMN count of > 500/μL; white blood cell count > 500/μL or positive bacterial cultures. This cut-off is recognized as more sensitive than other criteria (PMN > 500/μL; white blood cell count > 500/μL) for identifying SBP. SBP diagnosis based solely on bacterial culture is considered unreliable, since up to 60% of patients with increased PMN count are reported as culture-negative. In our study, all patients with culture-positive abdominal infection, including both SBP and secondary peritonitis patients, had elevated PMN counts. In the four SBP patients, the bacterial cultures were positive for only one (25.0%).

Our study measured calprotectin in ascitic fluid in 130 unselected samples from 71 consecutive patients. Ascitic calprotectin levels correlated well and reliably with PMN counts, and the samples with PMN > 250/μL also had higher ascitic calprotectin levels than the samples with

---

**Table 3 Test characteristics of ascitic calprotectin to identify > 250 polymorphonuclear leukocytes per mL ascites**

| Test          | AUC (95%CI) | Best cut-off (μg/mL) | Sens (%) | Spec (%) | LR+  | LR-  | PPV (%) | NPV (%) | Accuracy (%) |
|---------------|-------------|----------------------|----------|----------|------|------|--------|---------|--------------|
| ELISA         | 0.977 (0.933-0.995) | 0.63 | 94.8 | 89.2 | 8.76 | 0.86 | 60.0  | 99.0  | 98.0         |
| POC           | 0.982 (0.942-0.997) | 0.51 | 100  | 84.7 | 6.53 | 0.00 | 52.8  | 100   | 87.7         |

Area under the receiver operating characteristics curve (AUC) with corresponding sensitivity (Sens), specificity (Spec), positive and negative likelihood ratio (LR+, LR-), and negative and positive predictive values (NPV, PPV) for ascitic calprotectin to identify polymorphonuclear > 250/μL. Overall accuracy was calculated using the following formula: (true positive test results + true negative test results)/total population. ELISA: Enzyme-linked immunosorbent; POC: Point-of-care.

**Figure 1** Measurement of ascitic calprotectin with the enzyme-linked immunosorbent test and the point-of-care test (Bland Altman plot). The differences between the results of the enzyme-linked immunosorbent (ELISA) and point-of-care (POC) tests in each patient are plotted against the mean of the two measurements, showing the limits of agreement, defined as the mean ± 2 SD of the difference.

µg/mL (2.05-5.37) vs 0.38 µg/mL (0.38-0.41), P < 0.001 (Figure 2). Evaluation of the ascitic calprotectin measurement as a diagnostic test to identify patients with PMN count > 250/μL yielded an AUC of 0.977 (95%CI: 0.933-0.995) for the ELISA and an AUC of 0.982 (95%CI: 0.942-0.997) for the POC test. Furthermore, the two tests did not show significantly different diagnostic capacity (P = 0.246 vs ELISA) (Figure 3).

Using the optimal cut-off value from the ROC of ELISA (0.63 μg/mL), ascitic calprotectin yielded a sensitivity of 95%, a specificity of 89.2%, and an accuracy of 90.0% (Table 3). To identify all patients with PMN count > 250/μL and to obtain 100% test sensitivity, a slightly lower cut-off value (0.44 μg/mL) is necessary. However, use of this lower value is accompanied by lower specificity (82.9%) and lower LR+ (5.84).

Analysis of the POC test characteristics revealed a nearly identical profile to the ELISA characteristics (Table 3). The optimal cut-off value for POC (0.51 μg/mL) yielded a sensitivity of 100% and a specificity of 84.7%, with 6.53 LR+ and 0.0 LR-. The overall accuracy of the POC test was 87.7% (Figure 4).

Patients with false positive test results had PMN counts between 3 and 212 (median 70.0, IQR 35.0-127.5) for the ELISA, and between 3 and 197 (median 45.0, IQR 16.0-100.0) for the POC test.

The ELISA and POC test had similar diagnostic capability for identifying PMN > 250/μL in the subgroup of patients with liver cirrhosis (95 samples from 54 patients; ELISA AUC 0.987, and POC test AUC 0.982). In addition, when the ascites samples were analysed according to the SAAG > 11g/L (115 samples from 62 patients), the AUCs of ascitic calprotectin were 0.983 for the ELISA and 0.988 for the POC test (data not shown).

**Figure 2** Differences in ascetic calprotectin levels measured by the ELISA test and the POC test (Bland Altman plot). The differences between the results of the enzyme-linked immunosorbent (ELISA) and point-of-care (POC) tests in each patient are plotted against the mean of the two measurements, showing the limits of agreement, defined as the mean ± 2 SD of the difference. **Figure 3** Mean ascitic calprotectin levels by the ELISA test and the POC test (μg/mL).
has been suggested that a total cell count < 1000/μL is adi- 
ably available and clinicians frequently rely on total cell 
PMN count would have been missed by the bedside test. 
These results suggest that no patient with elevated 
NPVs of calprotectin testing in ascites were excellent 
therefore favoured over high specificity. In our study, the 
cations may occur. In screening tests, high sensitivity is 
for a specific disease, it is preferred to test all patients at 
ROC analysis). In a diagnostic test that is used to screen 
(95% and 100%, respectively) and high specificity (89% 
PMN > 250 cells/μL, and the point-of-care (POC) test (B). PMN: Polymorphonuclear.

Figure 2 Ascitic calprotectin values in patients with normal and elevated ascitic polymorphonuclear cell count. Box-and-whisker plot representing the median, 25th to 75th percentiles, minimum/maximum values, and outliers outside 1.5 times (circle) and 3 times (cross) the interquartile range of ascitic calprotectin values, measured with the enzyme-linked immunosorbent (ELISA) test (A) and the point-of-care (POC) test (B). PMN: Polymorphonuclear.

Figure 3 Receiver operating characteristics analysis of the enzyme-linked immunosorbent test and the point-of-care test to identify elevated ascitic polymorphonuclear cell count. The area under the receiver operating characteristics curve (AUC) for ascitic calprotectin for identifying a polymorphonuclear count > 250/μL. No differences between the two tests (P = 0.155) were detected. The diagonal line represents no discrimination. POC: Point-of-care; ELISA: Enzyme-linked immunosorbent.

PMN ≤ 250/μL. Both the ELISA and the POC test accurately measured ascitic calprotectin, and the correlation between the two tests was excellent with high sensitivity (95% and 100%, respectively) and high specificity (89% and 85%, respectively) at the optimal cut-off points (from ROC analysis). In a diagnostic test that is used to screen for a specific disease, it is preferred to test all patients at risk, especially when potentially life-threatening complications may occur. In screening tests, high sensitivity is therefore favored over high specificity. In our study, the NPVs of calprotectin testing in ascites were excellent (99% for the ELISA and 100% for the POC test). Notably, these results suggest that no patient with elevated PMN count would have been missed by the bedside test.

In daily clinical practice, PMN count is often not readily available and clinicians frequently rely on total cell count when initiating empiric antibiotic treatment[43]. It has been suggested that a total cell count < 1000/μL (obtained from automated cell counting procedures) is unlikely to signify SBP, having a NPV of 96%[44]. In our study, using such a criteria would have misclassified five patients (26.3%) with elevated PMN counts. Moreover, the use of total cell count in combination with ascitic calprotectin measurement did not increase the diagnostic accuracy of calprotectin testing, as calculated by ROC analysis (data not shown).

To avoid diagnostic delay, it has been proposed that automated PMN counting should replace the laborious and time-consuming manual cell counting technique[8,9]. Studies have demonstrated that automated blood cell counts correlate well with manual ascitic leukocyte differential counts[45]. However, despite the potential benefit of automated cell counters in clinical practice, widespread use of this technology is limited by the cost of the sophisticated laboratory equipment and requirement for trained operators; this is a particular challenge for practitioners’ office settings and small clinics without in-house laboratories.

The use of reagent strips (urine dipsticks) for PNM counting (by colorimetric detection of leukocyte esterase activity) has also been evaluated as a rapid SBP diagnostic tool[43,44]. A number of these studies have reported sensitivities between 85% and 100% and specificities between 90% and 100%/10-25. However, these results came from mostly single-centre studies with small numbers of SBP cases. The only large, multicentre study reported in the literature produced very different results; in particular, using 2123 paracenteses, the sensitivity was only 45% for identifying PMN > 250/μL in cirrhotic patients[26]. Although specificity was still high, it was concluded that urinary dipstick testing lacks sufficient accuracy for diagnosing SBP. The risk of false negative results seemed to be especially problematic in patients with lower PMN counts[46]. These results dampened the initial enthusiasm for reagent strips, and currently this method is not recommended for rapid diagnosis of SBP[46].

Only one study in the literature, to date, has provided data on calprotectin measurement in ascites[35]. In that study, Homann et al[44] compared ascites from patients with malignant disease to ascites from patients with non-
malignant disease. Higher ascitic calprotectin levels were found in the malignant patients and shown to correlate with increased mortality in patients with decompensated liver cirrhosis. However, the authors did not investigate the diagnostic potential of ascitic calprotectin. More recently, Parsi et al.\textsuperscript{[27]} measured ascitic lactoferrin (an iron-binding protein also found in PMNs) in cirrhotic patients with ascites and investigated its potential for identifying SBP. The lactoferrin measurements correctly identified PMN counts $> 250/\mu L$ in 22 of 218 samples (10.1%), yielding a sensitivity of 95.5% and specificity of 97.0%. However, the quantitative assay (ELISA) used in that study is not commercially available, and to date no bedside test, qualitative or quantitative, exists for lactoferrin.

The results from our current study confirm the findings reported by Parsi et al.\textsuperscript{[27]}. Specifically, we show that measurement of calprotectin, a leukocyte-specific protein, may serve as a surrogate marker for the PMN count in ascitic fluid. A particular strength of our study is the quantitative measurement of calprotectin by two methods, a laboratory-based ELISA and a commercially available bedside test. Rapid bedside measurement is advantageous for hospitalised patients, as it supports early antibiotic intervention and limits unnecessary treatments. It will also benefit the outpatient setting by providing on-site testing, since samples are otherwise required to be transported to an offsite laboratory. The POC test that we used can accomplish quantitative measurement of ascitic calprotectin within minutes, and this feature is expected to minimize the problems associated with diagnostic delay that clinicians currently face. Additionally, the cost of POC testing may be less than the other methods, such as contracting with the offsite laboratories.

There are several limitations to the current study that merit consideration. First, the prevalence of SBP in our study cohort was lower than expected from the literature. Second, we included all patients with ascites, irrespective of the aetiology, and it may be that our results cannot be generalised to all patients with liver cirrhosis. Third, this was an exploratory study that aimed to establish the concept of measuring a PMN-related inflammatory protein, rather than PNM cells themselves, as an indicator of elevated cell count in ascites; therefore, no formal sample size calculation was performed. Finally, our sample size was small and larger studies are needed to evaluate this test in different clinical settings and to establish a reliable cut-off for ascitic calprotectin for optimal identification of PMN counts $> 250/\mu L$.

In conclusion, we have demonstrated that measurement of calprotectin in ascitic fluid correlates well with the PMN count and reliably predicts levels $> 250/\mu L$. Additionally, we showed that an elevated PMN count could easily be measured by a POC test device which may enable a treating physician to obtain useful bedside measurements, especially those practicing in settings with limited equipment and/or technical personnel. Further studies are warranted to define a clinically useful cut-off for the diagnosis of SBP in cirrhotic patients with ascites.

**ACKNOWLEDGMENTS**

We would like to express our sincere gratitude to the patients and staff of the Gastroenterology Department, especially to Eric Pfifflimlin and Margot Brenneisen, and to the laboratory technicians, especially Chantal Brühlhardt, for their valuable efforts. In addition, we would like to thank Kathleen A Bucher for English language editing of the manuscript.

**COMMENTS**

**Background**

Ascites is the most common complication of patients with cirrhosis, and around 60% of patients will develop ascites within 10 years of disease commencement. Spontaneous bacterial peritonitis (SBP) is an important cause of morbidity and mortality in these patients. SBP is estimated to affect 10%-30% of hospitalised patients with ascites, and it is recommended that all patients with ascites undergo paracentesis at the time of admission to assess SBP status and initiate timely therapy.

**Research frontiers**

The diagnosis of SBP is based on a polymorphonuclear leukocyte (PMN) cell count $> 250/\mu L$ in the ascitic fluid. Currently, differential cell count is usually performed manually using light microscopy and counting chambers. This procedure is time consuming, and diagnosis may be further delayed when laboratory personnel are not readily available. Several other methods to diagnose SBP (automated cell counting and urine dipstick-based screening for leukocytes) have proven unreliable in clinical practice and are inferior to the manual method. In this study, authors investigated the potential of calprotectin, a neutrophilic

---

**Figure 4  Diagnostic accuracy.** For the enzyme-linked immunosorbent (ELISA) test, the overall test accuracy of ascitic calprotectin was 87% when 0.63 $\mu g/mL$ was used as the best cut-off value (A) and was 84% for the point-of-care (POC) test when 0.51 $\mu g/mL$ was used as best cut-off (B). PMN: Polymorphonuclear.
The rapid diagnosis of SBP and immediate start of antibiotic treatment is of paramount importance as mortality estimates approach 30%.

**Applications**

The rapid diagnosis of SBP is important for both inpatient and outpatient settings. Inpatient settings may benefit from more rapid diagnosis and immediate start of antibiotic treatment, while outpatient settings may benefit from a more rapid diagnostic process that can be performed at the patient’s home or a community clinic, minimizing the need for hospitalization.

**Terminology**

Calprotectin, a calcium and zinc-binding protein, is found almost exclusively in neutrophils. The presence of calprotectin in body fluids is proportional to the number of neutrophils. The presence of calprotectin in ascitic fluid correlates well with PMN count and reliably indicates PMN levels > 1000/µL. Additionally, we showed that an elevated PMN count could be easily measured within minutes using a point-of-care (POC) bedside test, suggesting its potential as a rapid diagnostic approach for SBP.

**REFERENCES**

1. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. *Gastroenterology* 2001; 120: 726-748 [PMID: 11179247 DOI: 10.1053/ gato.2001.22580]

2. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol* 2006; 44: 217-231 [PMID: 16298014 DOI: 10.1016/j.jhep.2005.10.013]

3. Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballeria J, Rodés J, Rozman C. Compensated cirrhosis: natural history and prognostic factors. *Hepatology* 1987; 7: 122-128 [PMID: 3804191 DOI: 10.1002/hep.1840070124]

4. Thuluvath PJ, Mors M, Thompson R. Spontaneous bacterial peritonitis—in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. *Am J Gastroenterol* 2001; 96: 1232-1236 [PMID: 11316175]

5. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. *J Hepatol* 2000; 32: 142-153 [PMID: 10763079 DOI: 10.1016/s0168-8278(00)00201-9]

6. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. *Hepatology* 2009; 49: 2087-2107 [PMID: 19475696 DOI: 10.1002/hep.22853]

7. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatoportal syndrome in cirrhosis. *J Hepatol* 2010; 53: 597-417 [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004]

8. Angelioni S, Niccolini G, Merli M, Nicolaio F, Pinto G, Aronne T, Attili AF, Riggio O. Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. *Am J Gastroenterol* 2003; 98: 1844-1848 [PMID: 12907342 DOI: 10.1111/j.1572-0241.2003.07620.x]

9. Cereto F, Genesca J, Segura R. Validation of automated blood cell counters for the diagnosis of spontaneous bacterial peritonitis. *Am J Gastroenterol* 2004; 99: 1480 [PMID: 15233685 DOI: 10.1111/j.1572-0241.2004.30348.x]

10. Vanbiervliet G, Rakotoarisoa C, Filippi J, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A. Diagnostic accuracy of a rapid urine-screening test (Multistix®) in cirrhotic patients with spontaneous bacterial peritonitis. *Eur J Gastroenterol Hepatol* 2002; 14: 1257-1260 [PMID: 12439122 DOI: 10.1097/00042737-200211000-00015]

11. Castellote J, López C, Gornals J, Tremosa G, Farina ER, Ballellas C, Domingo A, Xiol X. Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. *Hepatology* 2003; 37: 893-896 [PMID: 12669893 DOI: 10.1053/jhep.2003.50120]

12. Thévenot T, Cadranel JF, Nguyen-Khac E, Tilmant L, Tiry C, Welty S, Meunoug N. Diagnosis of spontaneous bacterial peritonitis in cirrhotic patients by use of two reagent strips. *Eur J Gastroenterol Hepatol* 2004; 16: 579-583 [PMID: 15167160 DOI: 10.1097/00042737-200406600-00011]

13. Butani RC, Shaffer RT, Szyjkowski RD, Weeks BE, Speights LG, Kadakia SC. Rapid diagnosis of infected ascitic fluid using leukocyte esterase dipstick testing. *Am J Gastroenterol* 2004; 99: 532-537 [PMID: 15056908 DOI: 10.1111/j.1572-0241.2004.04084.x]

14. Sapey T, Kabissa D, Fort E, Laurin C, Mendler MH. Instant diagnosis of spontaneous bacterial peritonitis using leukocyte esterase reagent strips: Nephur-Test vs. Multistix®. *Liver Int* 2005; 25: 343-348 [PMID: 15780060 DOI: 10.1016/j.jhep.2004.06.003]

15. Sapey T, Mena E, Fort E, Laurin C, Kabissa D, Runyon BA, Mendler MH. Rapid diagnosis of spontaneous bacterial peritonitis with leukocyte esterase reagent strips in a European and in an American center. *J Gastroenterol Hepatol* 2005; 20: 187-192 [PMID: 15683419 DOI: 10.1111/j.1440-1746.2004.03554.x]

16. Kim DY, Kim JH, Chon CY, Han KH, Ahn SH, Kim JK, Paik YH, Lee KS, Moon YM. Usefulness of urine strip test in the rapid diagnosis of spontaneous bacterial peritonitis. *Liver Int* 2005; 25: 1197-1201 [PMID: 16343072 DOI: 10.1016/j.jhep.2005.01.016]

17. Sarwar S, Alam A, Izhar M, Khan AA, Butt AK, Shafqat F, Malik K, Ahmed I, Niazi AK. Bedside diagnosis of spontaneous bacterial peritonitis using reagent strips. *J Coll Physicians Surg Pak* 2005; 15: 418-421 [PMID: 16197871]

18. Wisniewski B, Rautou PE, Al Sirafi Y, Lambare-Narcy B, Drouhin F, Constantini D, Fischer D, Labayle D, Denis J. [Diagnosis of spontaneous ascites infection in patients with cirrhosis: reagent strips]. *Presse Med* 2005; 34: 997-1000 [PMID: 16225251 DOI: 10.1016/S0755-4892(05)84098-9]

19. Campillo B, Richardet JP, Dupeyron C. Diagnostic value of two reagent strips (Multistix 8 SG and Combur 2 LN) in cirrhotic patients with spontaneous bacterial peritonitis and symptomatic bacterascites. *Gastroenterol Clin Biol* 2006; 30: 446-452 [PMID: 16633312 DOI: 10.1016/S0152-3802(06)73201-8]

20. Rerkninratr R, Rungsangmanoo W, Kongkam P, Kullavanijaya P. Efficacy of leukocyte esterase dipstick test as a rapid test in diagnosis of spontaneous bacterial peritonitis. *World J Gastroenterol* 2006; 12: 7183-7187 [PMID: 17131484]

21. Braga LA, Souza MH, Barbosa AM, Furtado FM, Campelo PA, Araújo Filho AH. Diagnosis of spontaneous bacterial peritonitis in cirrhotic patients in northeastern Brazil by use of rapid urine-screening test. *Sao Paulo Med J* 2006; 124: 141-144 [PMID: 17191690 DOI: 10.1590/S1516-31802006000300006]

22. Torus M, Dolar E, Yılmaz Y, Keskünn M, Kiyci M, Siniritas M, Sarandol E, Gurel S, Nak SG, Gulmen M. Evaluation of
Burri E et al. Calprotectin in ascs

leukocyte esterase and nitrite strip tests to detect spontaneous bacterial peritonitis in cirrhotic patients. World J Gastroenterol 2007; 13: 6027-6030 [PMID: 18023094 DOI: 10.3748/wjg.13.6027].

23 Gaya DR, David B Lyon T, Clarke J, Jamdar S, Inverarity D, Forrest EH, John Morris A, Stanley AJ. Bedside leucocyte esterase reagent strips with spectrophotometric analysis to rapidly exclude spontaneous bacterial peritonitis: a pilot study. Eur J Gastroenterol Hepatol 2007; 19: 289-295 [PMID: 17535692 DOI: 10.1097/MEG.0b013e328013f991].

24 Nobre SR, Cabral JE, Sofia C, Leitão MC. Value of reagent strips in the rapid diagnosis of spontaneous bacterial peritonitis. Hepatogastroenterology 2008; 55: 1020-1023 [PMID: 18705321].

25 Ribeiro TC, Kondo M, Amaral AC, Parise ER, Bragagno Junior MA, Souza AF. Evaluation of reagent strips for ascitic fluid leukocyte determination: is it a possible alternative for spontaneous bacterial peritonitis rapid diagnosis? Braz J Infect Dis 2007; 11: 70-74 [PMID: 17625731 DOI: 10.1590/S1413-86702007000100017].

26 Noutsos TB, Cadranel JF, Nahon P, Khac EN, Moreau R, Thévenot T, Nousbaum JB. Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. J Crohns Colitis 2010; 4: 134-140 [PMID: 22395735 DOI: 10.1016/j.crohns.2010.11.0116].

27 Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care test device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Clin Gastroenterol 2012; 46: 207-214 [PMID: 22251973 DOI: 10.1097/ MCG.0b013e3182387293].

28 Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004; 344: 37-51 [PMID: 15149869 DOI: 10.1016/j.cca.2004.02.023].

29 Soyfoo MS, Roth J, Vogt T, Pochet R, Decaux G. Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol 2009; 36: 2190-2194 [PMID: 19755614 DOI: 10.3899/jrheum.081302].

30 Frosch M, Strey A, Vogt T, Wulfraat NM, Kuis W, Sunderkötter C, Harms E, Sorg C, Roth J. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003; 49: 628-637 [PMID: 12802875 DOI: 10.1002/art.11657].

31 Jung SY, Park YB, Ha YJ, Lee KH, Lee SK. Serum calprotectin as a marker for disease activity and severity in adult-onset Still’s disease. J Rheumatol 2010; 37: 1029-1034 [PMID: 20231196 DOI: 10.3899/jrheum.091120].

32 Benoit S, Toksoy A, Ahlmann M, Schmidt M, Sunderkötter C, Foell D, Pasparakis M, Roth J, Goebeler M. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol 2006; 155: 62-66 [PMID: 16792753 DOI: 10.1111/j.1365-2133.2006.07198.x].

33 Raseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 93-98 [PMID: 10046733 DOI: 10.1080/00365529509127335].

34 Homann C, Christophsen E, Schlüchting P, Philipson EK, Graudel NA, Garred P. Ascites fluid and plasma calprotectin concentrations in liver disease. Scand J Gastroenterol 2003; 38: 415-420 [PMID: 12739714 DOI: 10.1080/003655203100008870].

35 van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369 [PMID: 20634346 DOI: 10.1136/bmj.c3369].

36 Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue® rapid test for faecal calprotectin. Ann Clin Biochem 2012; 49: 55-58 [PMID: 21930735 DOI: 10.1258/abc.2011.011106].

P-Reviewers Montalto G, Desai D, Gaya DR

S-Editor Wen LL L-Editor A E-Editor Xiong L